Compare EPC & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPC | IVVD |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.1M | 659.8M |
| IPO Year | 2000 | 2021 |
| Metric | EPC | IVVD |
|---|---|---|
| Price | $19.87 | $1.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $22.67 | $8.75 |
| AVG Volume (30 Days) | 580.3K | ★ 3.3M |
| Earning Date | 02-09-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $2,223,500,000.00 | $50,039,000.00 |
| Revenue This Year | $2.81 | $107.86 |
| Revenue Next Year | $1.62 | $146.53 |
| P/E Ratio | $36.91 | ★ N/A |
| Revenue Growth | N/A | ★ 332.71 |
| 52 Week Low | $15.88 | $0.44 |
| 52 Week High | $33.03 | $3.07 |
| Indicator | EPC | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 66.31 | 34.85 |
| Support Level | $18.58 | $2.15 |
| Resistance Level | $19.67 | $2.31 |
| Average True Range (ATR) | 0.60 | 0.15 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 73.68 | 11.44 |
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Wet Shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams. Sun and Skin Care consists of sun care products, men's and women's grooming products, Billie women's grooming products and personal wipe products. Feminine Care products include tampons, pads and liners. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.